Efficacy of psychological interventions for premenstrual syndrome: A systematic review and meta-analysis of randomized controlled trials.

J Affect DisordJul 16, 2026 (epub)
Clinical ResearchObstetrics & GynecologyPsychiatry

Yue Liu, Ruilin Wu, Xin Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of psychological interventions for premenstrual syndrome (PMS) in 1369 reproductive-aged women. The findings indicated that these interventions significantly reduced PMS symptom severity, with a standardized mean difference of -1.57 (95% CI [-1.94, -1.21], p < 0.001).

Key findings

  • Psychological interventions reduced PMS symptom severity with an SMD of -1.57.
  • Depressive symptoms were alleviated with an SMD of -1.08.
  • Anxiety symptoms showed a significant reduction with an SMD of -1.03.
  • Anger/irritability symptoms decreased with an SMD of -0.85.

Why it matters

Psychological interventions offer a non-pharmacological approach to managing PMS, potentially reducing reliance on medications that may have adverse effects. This could enhance patient care and quality of life for women experiencing PMS.

Source

PubMed · PMID 42448050

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.